

Unusual Transformation of the 3-Hydroxy-picolinoyl Residue of Pristinamycin I_A[†]

JEAN-MARC PARIS, JEAN FRANCOIS, CHRISTIAN MOLHERAT, FRANCA ALBANO,
MIREILLE ROBIN, MARC VUILHORGNE and JEAN-CLAUDE BARRIERE*

Rhône-Poulenc Rorer S.A., Centre de Recherche de Vitry-Alfortville,
13 quai Jules Guesde, BP-14-94403-Vitry sur Seine Cedex, France

(Received for publication February 23, 1995)

Pristinamycin I_A was modified in a two-step procedure to give original derivatives possessing a tricyclic nucleus (**8a**, **8b**, **8c**) or a substituted pyrrole ring (**10a**, **10b**) in place of the natural exocyclic 3-hydroxy-picolinoyl residue. This transformation involved firstly preparation of pyridinium betaines **5** from pristinamycin I_A and secondly a 1~3 dipolar cycloaddition between **5** and *N*-substituted maleimides or diethyl acetylenedicarboxylate. The compounds obtained were evaluated as antibacterial agents alone and in association with pristinamycin II_A.


Among the large number of antibiotics that inhibit protein synthesis in prokaryotic cells, the streptogramins are unique in that they consist of two kinds of structurally unrelated molecules, group A and group B^{1,2)} (Fig. 1).

Group A and B streptogramins act in synergy both *in vitro* and *in vivo*. The synergy between them results in a greater potency and a broader spectrum of antibacterial activity than those of each component alone, rendering the mixture bactericidal against a wide variety of Gram-positive bacteria. Since their discovery, intensive efforts have been made to synthesize modified analogues of the two groups of constituents^{3,4)} and to elucidate the mechanism of action of the streptogramins^{5~7)}. We recently reported some of our results in the streptogramin field which resolved the problem of the poor water solubility of the two constituents and which led to the selection for clinical trials of the first semi-synthetic injectable streptogramin, derived from pristinamycin I

and II (RP 59500)^{4,8)}.

In the course of our continuing program aimed at chemically modified group B streptogramins, we have been particularly interested in the modification of the characteristic 3-hydroxy-picolinoyl exocyclic residue of pristinamycin I_A **1** (Fig. 1). This residue is an unusual feature in natural antibiotics and is probably involved in the mechanism of action of the streptogramins: it is thought to form a salt bridge with suitable acceptor atoms of the ribosome⁶⁾. In this context, we attempted to replace or modify this residue, in order to clarify the role of this nucleus in antibacterial activity. We report in this paper an unusual reaction observed during functionalisation of this residue involving firstly, formation of pyridinium betaines **5** and secondly their transformation *via* a cycloaddition reaction into tricyclic systems **8** or into unexpected substituted pyrrole derivatives **10**.

Fig. 1. Structure of representative streptogramins.



[†] This article is a special contribution in honour of Professor SATOSHI ŌMURA's 60th birthday.

Results

The alkylation of group B streptogramins can lead to 3 products depending on the reaction conditions used^{10~14}). Diazomethane alkylates both the hydroxyl group and the pyridyl-nitrogen of the picolinic acid residue, affording a mixture of the betaine (**5a**, R=Me) and, as the minor product, the methyl ether (**6**, R=Me). Pristinamycin I_A reacts with methyl iodide or methylsulfate, yielding selectively the quaternary ammonium salt **4** of the 4-dimethylamino function.

Betaines **5** were successfully obtained in fair to good yields by treating pristinamycin I_A with a reactive diazoalkane or merely by reacting it with an appropriate alkyl halide in DMF in the presence of potassium fluoride (Method A) or caesium fluoride (Method B), by analogy with the results described for virginiamycin S¹³) (Scheme 1). The betaines **6** could be purified by flash-chromatography in order to eliminate side-products resulting from the *O*-alkylation of the hydroxyl group and from extended *N*-alkylation resulting in the formation of minor species **7**.

As 3-oxido-pyridinium betaines are known to act as 1,3-dipoles and to undergo 1,3-dipolar additions with a great variety of dipolarophiles,^{15~17}) we investigated this type of reaction with pristinamycin I_A betaines using electron-deficient olefins, such as methyl or phenyl

maleimide and diethyl acetylenedicarboxylate.


Pristinamycin betaines **5** reacted in the expected way with *N*-methyl and *N*-phenyl maleimide in refluxing 1,2-dichloroethane to give rise, after purification by flash-chromatography, to the *exo* adduct **8** (Scheme 2).

The thermodynamically stable *exo* product **8** was obtained (up to 90%) during this concerted cycloaddition; this compound is probably favoured by steric factors and dipole interactions. The evidence for structure **8** (*exo*) was mainly obtained from the coupling constants obtained by ¹H NMR data and was confirmed by NOE experiments, no NOE interaction occurred between the NCH₃ and the bridge head protons of maleimide moieties.

When heated in the presence of diethyl acetylenedicarboxylate, pristinamycin betaines **5** yielded the unexpected pyrroles **10a~10b** via an original process (Scheme 3).

Reaction of simple 3-oxido-pyridiniums with diethyl acetylenedicarboxylate led generally to the normal 2~6 adduct **9**. Formation of pyrrole **10**, which was the only product characterised in this reaction, is an original reaction and can be viewed as a formal removal of acetylene and CO from **9**. Compounds **5a~5c**, **8a~8c** and **10a~10c** were tested *in vitro* for antimicrobial activity against several genera. None had shown potent activity on any of the strains tested, either alone or

Scheme 1. Alkylation reactions on pristinamycin I_A.







Fig. 2. ^aNOE interactions observed for compound **8a**.
^a The expected NOE were recorded at 250 MHz in CDCl₃.




Table I. Preparation of tricyclic adducts and of pyrrole derivatives from **1**.

Compound No.	R ₁	R ₂	Method ^a Step 1	Yield (%) ^b Step 1, Step 2
8a	Me	Me	A	71/41
8b	Et	C ₆ H ₅	A	60/56
8c	CH ₂ CO ₂ Et	C ₆ H ₅	B	45.9/51
10a	Me	CO ₂ Et	A	71/64
10b	Et	CO ₂ Et	A	60/69

^a Reaction conditions. Step 1 Method A: RX, KF, DMF, Method B: RX, CsF, DMF.

^b Yields are not optimised.

combined with pristinamycin II_A.

Conclusion

In conclusion, different modifications of the 3-hydroxy-picolinoyl residue of pristinamycin I_A have been performed. From a chemical point of view, the ease of formation of the betaines and their transformation into various cycloadducts can be noted. Noteworthy also is the original formation of the pyrrole moiety **10** obtained during this study. Generalization of this reaction to different substrates is currently underway in our laboratory.

The biological results obtained with modified pristinamycins I_A clearly indicate the importance of the 3-

hydroxy pyridine ring for the antimicrobial activity of pristinamycin I_A. Betaines **5** were found to be totally inactive alone or in association with pristinamycin II_A against both erythromycin-sensitive (Ery^s) and resistant (Ery^r) strains of *Staphylococcus aureus*. Replacement of the 3-hydroxy-picolinoyl residue of pristinamycin I_A by a tricyclic ring system or by a pyrrole ring also yielded compounds that had no detectable antibacterial activity.

Experimental

Reagents were used as supplied unless otherwise noted and were purchased from Prolabo or Janssen Chemica.

Melting points were recorded on a Köfeler apparatus and were not corrected. ^1H NMR spectra were recorded on Bruker AC 250 (250 MHz) or AM 400 (400 MHz) spectrometers. Chemical shifts (δ) are reported in ppm relative to internal tetramethylsilane. The atoms of pristinamycin I_A are numbered according to the method used by ANTEUNIS and co-workers¹⁸⁾ for virginiamycin S. Infrared spectra (IR) were determined with a Perkin-Elmer Model 938G or 580B. Mass spectra (MS) were recorded on a Kratos AEI MS50 spectrometer (FAB, matrice used *m*-nitro benzyl alcohol, reacting gaz Xenon, 8 eV). Unless otherwise noted, all the compounds presented a pseudo molecular ion at $m/z = \text{MH}^+$. Satisfactory spectral data were obtained for all new compounds. Crude products were purified by flash column chromatography on silica gel (0.04~0.063 mm; Merck). For thin layer chromatography (TLC), 250 μm E. Merck silica gel 60 F₂₅₄ plates were used. Evaporations were in most cases carried out below 30~35°C. Pristinamycin I_A used in this study was obtained from the bulk pharmaceutical and purified as described¹⁹⁾.

Formation of Pristinamycin I_A Betaines

(*N*-Methyl 3-oxydo 2-pyridinio-1 carbonyl)-1-des(-3-hydroxy-picolinoyl) Pristinamycin I_A **5a**

In a three-necked round-bottomed flask were successively added under N_2 atmosphere, anhydrous DMF (50 ml), KF (1.68 g, 24.9 mmol) and MeI (0.9 ml, 15 mmol). After 2 minutes **1a** (10.6 g, 11.9 mmol) was added and the mixture stirred for 15 hours at room temperature then for 1 hour at 50°C. After cooling, the reaction mixture was partitioned between a saturated NaHCO_3 solution (300 ml) containing NaCl (5 g) and ethyl acetate (100 ml). The aqueous layer was separated and washed with ethyl acetate (100 ml). Then the organic layers were pooled, and distilled water (200 ml) was added. The pH of the aqueous layer was adjusted to 3.5 by hydrochloric acid and the organic layer was separated and washed with water (50 ml). The aqueous layers were adjusted to pH 7 with solid NaHCO_3 then washed with dichloromethane (3 \times 50 ml). The organic layers were pooled, dried over MgSO_4 , and concentrated to yield 7.2 g (71%) of **5a** as a yellow powder which could be used without further purification in the cycloaddition reaction.

An analytical sample of **5a** can be obtained by flash-chromatography using CH_2Cl_2 - MeOH (96 : 4) as eluent to yield **5a** as a white-yellow solid (mp 254°C dec., lit.¹¹⁾ 260~270°C dec.).

^1H NMR (400 MHz, CDCl_3) δ : 0.60 (dd, $J=16$ and 5.5 Hz, 1H: 5 β); 0.89 (t, $J=7.5$ Hz, 3H: CH_3 2 γ); 1.15 (m, 1H: 3 β); from 1.15 to 1.30 (m, 1H: 3 γ); 1.25 (d, $J=6.5$ Hz, 3H: CH_3 1 γ); 1.53 (m, 1H: 3 γ); 1.65 and 1.75 (2 m, 1H each: CH_2 2 β); 1.98 (m, 1H: 3 β); 2.19 and 2.32 (respectively m and m, $J=16$ Hz, 1H each: CH_2 5 δ); 2.46 (d, $J=16$ Hz, 1H: 5 β); 2.85 (m, $J=13$ and 3.5 Hz, 1H: 5 ϵ); 2.90 (s, 6H: $\text{N}(\text{CH}_3)_2$); 2.92 (dd, $J=12$ and 4 Hz, 1H: 4 β); 3.24 and 3.54 (2m, 1H each: CH_2 3 δ); 3.26 (s,

3H: NCH_3 4); 3.31 (t, $J=12$ Hz, 1H: 4 β); 4.53 (s, 3H: N^+CH_3); 4.59 (dd, $J=8$ and 6.5 Hz, 1H: 3 α); 4.75 (br dd, $J=13$ and 8 Hz, 1H: 5 ϵ); 4.83 (m, $J=9$ and 7.5 Hz, 1H: 2 α); 5.00 (dd, $J=9.5$ and 1.5 Hz, 1H: 1 α); 5.46 (dd, $J=12$ and 4 Hz, 1H: 4 α); 5.84 (m, $J=6.5$ and 1.5 Hz, 1H: 1 β); 5.89 (d, $J=9.5$ Hz, 1H: 6 α); 5.92 (br d, $J=5.5$ Hz, 1H: 5 α); 6.58 (d, $J=8.5$ Hz, 2H: H Aromatics in 4 ϵ); 6.81 (d, $J=9$ Hz, 1H: NH 2); 7.09 (d, $J=8.5$ Hz, 2H: H Aromatics in 4 δ); from 7.15 to 7.40 (m, 8H: H Aromatics in 6-1' H_4 ~1' H_5 and 1' H_6); 8.85 (d, $J=9.5$ Hz, 1H: NH 6); 12.88 (d, $J=9.5$ Hz, 1H: NH 1).

Anal Calcd for $\text{C}_{46}\text{H}_{56}\text{N}_8\text{O}_{10}$:

C 62.71 H 6.41, N 12.72, O 18.16

Found: (1,6 H_2O)

C 62.34, H 6.39, N 12.30, O 17.89

(*N*-Ethyl 3-oxydo 2-pyridinio-1 carbonyl)-1-des(-3-hydroxy-picolinoyl) Pristinamycin I_A **5b**

Ethyl iodide (1.2 ml, 15 mmol) was added to potassium fluoride (1.67 g, 24.9 mmol) in anhydrous DMF (50 ml). After 2 minutes, pristinamycin I_A was added. The reaction mixture was stirred for 16 hours at room temperature then for 3 hours at 50°C. The reaction mixture was cooled and then poured into a saturated NaHCO_3 solution; The product was extracted with ethyl acetate (2 \times 100 ml) then with dichloromethane (3 \times 100 ml). The organic layers were dried over MgSO_4 , then concentrated to dryness below 30°C. The resulting solid was partitioned between ethyl acetate (100 ml) and distilled water. The pH of the aqueous layer was adjusted to 3 by hydrochloric acid. The organic layer was separated and washed with water (50 ml). The aqueous layers were adjusted to pH 7 with solid NaHCO_3 then washed with dichloromethane (100 ml then 2 \times 50 ml). The organic layers were pooled, dried over MgSO_4 , and concentrated to give 6.14 g (60%) of **5b** as yellow powder (94% purity containing 6% of *O*-alkyl derivative) which can be used without further purification for the cycloaddition reaction.

This product can be purified by flash-chromatography by using dichloromethane - methanol (94 : 6) as eluant to yield 2.2 g (36% yield) of **5b** as yellow solid (mp 230°C).

^1H NMR (400 MHz, CDCl_3) δ : 0.60 (dd, $J=16$ and 5.5 Hz, 1H: 5 β); 0.89 (t, $J=7.5$ Hz, 3H: CH_3 2 γ); 1.14 (m, 1H: 3 β); 1.27 (d, $J=6.5$ Hz, 3H: CH_3 1 γ); 1.32 and 1.58 (2m, 1H each: CH_2 3 γ); 1.67 (t, $J=7.5$ Hz, 3H: CH_3 ethyl); 1.67 and 1.78 (2m, 1H each: CH_2 2 β); 2.02 (m, 1H: 3 β); 2.18 and 2.32 (2m, respectively $J=16$, 12.5 and 8 Hz and $J=16$ Hz, 1H each: CH_2 5 δ); 2.38 (d, $J=16$ Hz, 1H: 5 β); 2.84 (m, $J=12.5$ and 4.5 Hz, 1H: 5 ϵ); 2.90 (s, 6H: $\text{N}(\text{CH}_3)_2$); 2.96 (dd, $J=12$ and 4 Hz, 1H: 4 β); 3.28 (s, 3H: NCH_3 4); 3.32 (t, $J=12$ Hz, 1H: 4 β); 3.32 and 3.58 (2m, 1H each: CH_2 3 δ); 4.59 (dd, $J=8$ and 7 Hz, 1H: 3 α); 4.75 (br dd, $J=12.5$ and 8 Hz, 1H: 5 ϵ); 4.86 (m, $J=9.5$ and 6.5 Hz, 1H: 2 α); 4.92 and 5.12 (m, $J=13$ and 7.5 Hz, 2H: N^+CH_2 ethyl); 5.04 (br d, $J=9.5$ Hz, 1H: 1 α); 5.51 (dd, $J=12$ and 4 Hz, 1H: 4 α); 5.85 (m, $J=6.5$ Hz, 1H: 1 β); 5.87 (d, $J=10$ Hz, 1H: 6 α);

5.92 (br d, $J=5.5$ Hz, 1H: 5 α); 6.60 (d, $J=8.5$ Hz, 2H: H Aromatics in 4 ϵ); 6.98 (d, $J=9.5$ Hz, 1H: NH 2); 7.16 (d, $J=8.5$ Hz, 2H: H Aromatics in 4 δ); from 7.15 to 7.30 (m, 6H: H Aromatics in 6 and 1'H₅); 7.33 (br d, $J=5$ Hz, 1H: 1'H₆); 7.38 (br d, $J=8.5$ Hz, 1H: 1'H₄); 8.87 (d, $J=10$ Hz, 1H: NH 6); 12.76 (d, $J=9.5$ Hz, 1H: NH 1).

Anal Calcd for C₄₇H₅₈N₈O₁₀:

C 63.07, H 6.53, N 12.52, O 17.88

Found: (1.38% H₂O)

C 62.73, H 6.58, N 12.62, O 17.50

(*N*-Methyl carboxyethyl 3-oxydo 2-pyridinio-1 carbonyl)-1-des(-3-hydroxy-picolinoyl) Pristinamycin I_A **5c**

Bromo ethyl acetate (1.034 g, 6.18 mmol) was added to caesium fluoride (1.88 g, 12.3 mmol) in anhydrous DMF (10 ml). After 2 minutes, pristinamycin I_A (4.65 g, 5.24 mmol) was added and the reaction mixture stirred for 17 hours at 80°C. After cooling, the reaction mixture was poured slowly into a saturated NaHCO₃ solution (100 ml). The yellow precipitate was filtered then washed with a saturated NaHCO₃ solution (2 × 50 ml) and then with hexane (2 × 50 ml). The resulting solid was dissolved in ethyl acetate (70 ml), filtered and washed with water adjusted to pH 3.5 with hydrochloric acid. The organic layer was separated then washed with water (50 ml). The aqueous layers were pooled, washed with ethyl acetate (40 ml), neutralized to pH 7 by addition of an aqueous NaHCO₃ solution, and then extracted with dichloromethane (3 × 75 ml). The organic layer was dried over MgSO₄ and evaporated to give 2.21 g (45.9% yield) of **5c**, which was used, without further purification, for the cycloaddition reaction.

¹H NMR (400 MHz, CDCl₃) δ : 0.70 (dd, $J=16$ and 6 Hz, 1H: 5 β); 0.87 (t, $J=7.5$ Hz, 3H: CH₃ 2 γ); 1.14 (m, 1H: 3 β); 1.20 (d, $J=6.5$ Hz, 3H: CH₃ 1 γ); from 1.20 to 1.35 (m, 1H: 3 γ); 1.27 (t, $J=7.5$ Hz, 3H: CH₃ ethyl); 1.51 (m, 1H: 3 γ); 1.58 and 1.73 (2m, 1H each: CH₂ 2 β); 1.96 (m, 1H: 3 β); 2.17 and 2.30 (respectively m and m, $J=16$ Hz, 1H each: CH₂ 5 δ); 2.43 (d, $J=16$ Hz, 1H: 5 β); 2.83 (m, $J=13.5$ and 4 Hz, 1H: 5 ϵ); 2.86 (s, 6H: N(CH₃)₂); 2.92 (dd, $J=12$ and 4.5 Hz, 1H: 4 β); 3.20 and 3.51 (2 m, 1H each: CH₂ 3 δ); 3.22 (s, 3H: NCH₃ 4); 3.27 (t, $J=12$ Hz, 1H: 4 β); 4.26 (q, $J=7.5$ Hz, 2H: COOCH₂ ethyl); 4.56 (dd, $J=8$ and 7 Hz, 1H: 3 α); 4.72 (br dd, $J=13.5$ and 8 Hz, 1H: 5 ϵ); 4.80 (m, $J=9$ and 7.5 Hz, 1H: 2 α); 4.93 (br d, $J=10$ Hz, 1H: 1 α); 5.25 and 5.62 (2d, $J=17$ Hz, 2H: N⁺CH₂COO); 5.49 (dd, $J=12$ and 4.5 Hz, 1H: 4 α); 5.78 (m, $J=6.5$ Hz, 1H: 1 β); 5.84 (d, $J=10$ Hz, 1H: 6 α); 5.96 (br d, $J=6$ Hz, 1H: 5 α); 6.57 (d, $J=8.5$ Hz, 2H: H Aromatics in 4 ϵ); 6.78 (d, $J=9$ Hz, 1H: NH 2); 7.08 (d, $J=8.5$ Hz, 2H: H Aromatics in 4 δ); from 7.10 to 7.30 (m, 7H: H Aromatics in 6-1'H₅ and 1'H₆); 7.38 (br d, $J=8.5$ Hz, 1H: 1'H₄); 8.84 (d, $J=10$ Hz, 1H: NH 6); 12.87 (d, $J=10$ Hz, 1H: NH 1).

Anal Calcd for C₄₉H₆₀N₈O₁₂:

C 61.75, H 6.35, N 11.76, O 20.14

Found:

C 61.12, H 6.30, N 10.70, O n.d.

Formation of Tricyclic Adducts

Analogue **8a**

N-Methyl maleimide (0.57 g, 5.1 mmol) was added to a stirred solution of *N*-methylpyridinium pristinamycin I_A betaine **5a** (1.5 g, 1.7 mmol) in 1,2-dichloroethane. The mixture was refluxed for 20 hours then an additional amount of *N*-methyl maleimide (0.38 g, 3.4 mmol) was added. After 5.5 hours, the mixture was evaporated to dryness to yield 2.55 g of a yellow solid which was purified by 2 successive flash-chromatographies by using dichloromethane-methanol (96:4) as eluant. This yielded 0.87 g of a solid which was recrystallized in 4 ml of propanol to yield 0.70 g (41% yield) of **8a** as yellow crystals (mp 222°C).

¹H NMR (400 MHz, CDCl₃) δ : 0.63 (dd, $J=16$ and 6 Hz, 1H: 5 β); 0.98 (t, $J=7.5$ Hz, 3H: CH₃ 2 γ); 1.14 (m, 1H: 3 β); 1.25 (d, $J=6.5$ Hz, 3H: CH₃ 1 γ); 1.31 and 1.60 (2 m, 1H each: CH₂ 3 γ); 1.85 and 1.93 (2 m, 1H each: CH₂ 2 β); 2.03 (m, 1H: 3 β); 2.25 and 2.40 (respectively m and m, $J=16$ Hz, 1H each: CH₂ 5 δ); 2.42 (s, 3H: NCH₃ 9'); 2.45 (d, $J=16$ Hz, 1H: 5 β); from 2.85 to 3.00 (m, 2H: 5 ϵ and 4 β); 2.92 (s, 6H: N(CH₃)₂); 3.12 (s, 3H: NCH₃ 3'); 3.28 (s, 3H: NCH₃ 4); 3.30 (t, $J=12$ Hz, 1H: 4 β); 3.37 and 3.47 (2d, $J=7.5$ Hz, 1H each: H3'a and H8'a); 3.67 (m, 2H: CH₂ 3 δ); 4.43 (d, $J=5$ Hz, 1H: H8'); 4.56 (dd, $J=7.5$ and 7 Hz, 1H: 3 α); 4.78 (br dd, $J=13$ and 8 Hz, 1H: 5 ϵ); 4.95 (m, $J=9.5$ and 7.5 Hz, 1H: 2 α); 5.05 (dd, $J=10$ and 1.5 Hz, 1H: 1 α); 5.34 (dd, $J=12$ and 4 Hz, 1H: 4 α); 5.67 (br d, $J=6$ Hz, 1H: 5 α); 5.93 (m, $J=6.5$ Hz, 1H: 1 β); 5.98 (d, $J=10$ Hz, 1H: 6 α); 6.17 (d, $J=9$ Hz, 1H: H6'); 6.57 (d, $J=8.5$ Hz, 2H: H Aromatics in 4 ϵ); 7.02 (d, $J=8.5$ Hz, 2H: H Aromatics in 4 δ); from 7.25 to 7.40 (m, 6H: H Aromatics in 6 and H7'); 8.09 (d, $J=9.5$ Hz, 1H: NH 2); 8.84 (d, $J=10$ Hz, 1H: NH 6); 8.97 (d, $J=10$ Hz, 1H: NH 1).

Anal Calcd for C₅₁H₆₁N₉O₁₂:

C 61.74, H 6.20, N 12.71, O 19.35

Found: (propanol 3.4%, H₂O 1.8%)

C 61.72, H 6.31, N 12.48, O 19.25

Analogue **8b**

N-Phenyl maleimide (5.8 g, 3.4 mmol) was added to a stirred solution of *N*-ethyl pyridinium pristinamycin I_A betaine **5b** (6 g, 6.7 mmol) in 1,2-dichloroethane (100 ml). The mixture was refluxed for 20 hours then evaporated to dryness to give a beige solid which was stirred in diethylether (250 ml), filtered, then purified by flash-chromatography by using dichloromethane-methanol (97:3) as eluant. This yielded 4 g (56% yield) of **8b** as a yellow solid (mp 200°C).

¹H NMR (400 MHz, CDCl₃) δ : 0.65 (dd, $J=16$ and 6 Hz, 1H: 5 β); 0.83 (t, $J=7.5$ Hz, 3H: CH₃ 2 γ); from 1.00 to 1.20 (m, 1H: 3 β); 1.08 (t, $J=7$ Hz, 3H: CH₃ ethyl); from 1.15 to 1.35 (m, 1H: 3 γ); 1.22 (d, $J=6.5$ Hz, 3H: CH₃ 1 γ); 1.55 (m, 1H: 3 γ); from 1.60 to 1.85 (m, 2H: CH₂ 2 β); 1.97 (m, 1H: 3 β); 2.20 and 2.35 (respectively m and m, $J=16$ Hz, 1H each: CH₂ 5 δ); 2.40 (d, $J=16$ Hz, 1H: 5 β); 2.44 and 2.72 (2m, $J_{AB}=12$ Hz, 1H each: NCH₂

ethyl); from 2.80 to 2.95 (m, 1H: 5 ϵ); 2.89 (s, 6H: N(CH₃)₂); 2.92 (dd, $J=12$ and 4 Hz, 1H: 4 β); 3.24 (s, 3H: NCH₃ 4); 3.25 (t, $J=12$ Hz, 1H: 4 β); 3.50 and 3.57 (2d, $J=7.5$ Hz, 1H each: H3'a and H8'a); 3.60 (m, 2H: CH₂ 3 δ); 4.53 (dd, $J=7$ and 6.5 Hz, 1H: 3 α); 4.64 (d, $J=5$ Hz, 1H: H8'); 4.73 (brdd, $J=13$ and 7.5 Hz, 1H: 5 ϵ); 4.85 (m, $J=9.5$ and 7.5 Hz, 1H: 2 α); 5.02 (dd, $J=10$ and 1.5 Hz, 1H: 1 α); 5.35 (dd, $J=12$ and 4 Hz, 1H: 4 α); 5.67 (br d, $J=6$ Hz, 1H: 5 α); 5.88 (m, $J=6.5$ and 1.5 Hz, 1H: 1 β); 5.95 (d, $J=10$ Hz, 1H: 6 α); 6.13 (d, $J=10$ Hz, 1H: H6'); 6.56 (d, $J=8.5$ Hz, 2H: H Aromatics in 4 ϵ); 7.01 (d, $J=8.5$ Hz, 2H: H Aromatics in 4 δ); from 7.20 to 7.35 (m, 6H: H Aromatics in 6 and H7'); 7.35 (d, $J=8$ Hz, 2H: H in *ortho* of Aromatics in 2'); 7.42 (t, $J=8$ Hz, 1H: H in *para* of Aromatics in 2'); 7.48 (t, $J=8$ Hz, 2H: H in *meta* of Aromatics in 2'); 7.88 (d, $J=9.5$ Hz, 1H: NH 2); 8.82 (d, $J=10$ Hz, 1H: NH 6); 9.10 (d, $J=10$ Hz, 1H: NH 1).

Anal Calcd for C₅₇H₆₅N₉O₁₂:

C 64.10, H 6.13, N 11.80, O 17.97

Found: (H₂O 1.2%)

C 64.08, H 5.92, N 11.75, O n.d.

Analogue 8c

N-Phenyl maleimide (1.70 g, 10.1 mmol) was added to a stirred solution of *N*-methyl carboxymethyl pyridinium betaine **5c** (2 g, 2.05 mmol) in 1,2-dichloroethane (50 ml). The mixture was refluxed for 20 hours then evaporated to dryness to yield 1.86 g of a beige solid which was purified by flash-chromatography by using dichloromethane-methanol (95:5) as eluant. This yielded 1.8 g (51% yield) of **8c** as a yellow solid (mp 190~200°C).

¹H NMR (400 MHz, CDCl₃) δ : 0.65 (dd, $J=16$ and 6 Hz, 1H: 5 β); 0.83 (t, $J=7.5$ Hz, 3H: CH₃ 2 γ); 1.10 (m, 1H: 3 β); 1.19 (t, $J=7$ Hz, 3H: CH₃ ethyl); 1.23 (d, $J=6.5$ Hz, 3H: CH₃ 1 γ); 1.25 and 1.53 (2m, 1H each: CH₂ 3 γ); from 1.60 to 1.80 (m, 2H: CH₂ 2 β); 1.97 (m, 1H: 3 β); 2.21 and 2.37 (respectively m and m, $J=16$ Hz, 1H each: CH₂ 5 δ); 2.42 (d, $J=16$ Hz, 1H: 5 β); from 2.80 to 2.95 (m, 1H: 5 ϵ); 2.88 (s, 6H: N(CH₃)₂); 2.93 (dd, $J=12$ and 4 Hz, 1H: 4 β); 3.26 (s, 3H: NCH₃ 4); 3.27 (t, $J=12$ Hz, 1H: 4 β); 3.44 and 3.49 (2d, $J=7.5$ Hz, 1H each: H3'a and H8'a); 3.50 and 3.54 (2d, $J=16$ Hz, 1H each: NCH₂); 3.60 (m, 2H: CH₂ 3 δ); 4.10 (m, 2H: COOCH₂ ethyl); 4.53 (dd, $J=7$ and 6 Hz, 1H: 3 α); 4.73 (br dd, $J=13$ and 8 Hz, 1H: 5 ϵ); 4.81 (d, $J=5$ Hz, 1H: H8'); 4.85 (m, $J=9.5$ and 7.5 Hz, 1H: 2 α); 4.99 (dd, $J=10$ and 1.5 Hz, 1H: 1 α); 5.37 (dd, $J=12$ and 4 Hz, 1H: 4 α); 5.67 (br d, $J=6$ Hz, 1H: 5 α); 5.89 (m, $J=6.5$ and 1.5 Hz, 1H: 1 β); 5.97 (d, $J=10$ Hz, 1H: 6 α); 6.13 (d, $J=10$ Hz, 1H: H6'); 6.55 (d, $J=8.5$ Hz, 2H: H Aromatics in 4 ϵ); 6.98 (d, $J=8.5$ Hz, 2H: H Aromatics in 4 δ); from 7.15 to 7.35 (m, 5H: H Aromatics in 6); 7.34 (d, $J=8$ Hz, 2H: H in *ortho* of Aromatics in 2'); 7.40 (dd, $J=10$ and 5 Hz, 1H: H7'); 7.41 (t, $J=8$ Hz, 1H: H in *para* of Aromatics in 2'); 7.47 (t, $J=8$ Hz, 2H: H in *meta* of Aromatics in 2'); 8.08 (d, $J=9.5$ Hz, 1H: NH 2); 8.82 (d, $J=10$ Hz, 1H: NH 6); 9.06 (d, $J=10$ Hz, 1H: NH 1).

Anal Calcd for C₅₉H₆₇N₉O₁₄:

C 62.92, H 6.00, N 11.19, O 19.89

Found: (propanol 3.4%)

C 63.22, H 6.00, N 11.09, O n.d.

Formation of Pyrrole Adducts

N-Methyl Pyrrole 10a

To a solution of *N*-methyl 3-pyridinium pristinamycin I_A betaine **5a** (7 g, 7.5 mmol) in 1,2-dichloroethane (70 ml) diethyl acetylenedicarboxylate (13 g, 75.5 mmol) was added. The mixture was refluxed for 21 hours, evaporated to dryness then purified by two successive flash-chromatographies for which first dichloromethane-methanol (97:3), then toluene-ethanol (90:10) was used as eluant. After concentration, the resulting solid was stirred in pentane (2 × 20 ml), filtered, then dried to yield 1.53 g (20% yield) of **10a** as beige solid (mp 190°C).

¹H NMR (400 MHz, CDCl₃) δ : 0.25 (dd, $J=16$ and 6 Hz, 1H: 5 β); 0.91 (t, $J=7.5$ Hz, 3H: CH₃ 2 γ); from 1.10 to 1.40 (m, 2H: 3 β and 3 γ); 1.25 (d, $J=7$ Hz, 3H: CH₃ 1 γ); 1.31 and 1.36 (2t, $J=7.5$ Hz, 3H each: CH₃ ethyl); 1.54 (m, 1H: 3 γ); from 1.55 to 1.80 (m, 2H: CH₂ 2 β); 2.03 (m, 1H: 3 β); 2.11 and 2.20 (respectively m and m, $J=16$ Hz, 1H each: CH₂ 5 δ); 2.20 (d, $J=16$ Hz, 1H: 5 β); 2.75 (m, $J=13$ and 4 Hz, 1H: 5 ϵ); 2.87 (s, 6H: N(CH₃)₂); 2.93 (dd, $J=12.5$ and 4.5 Hz, 1H: 4 β); 3.18 and 3.45 (2m, 1H each: CH₂ 3 δ); 3.20 (t, $J=12.5$ Hz, 1H: 4 β); 3.25 (s, 3H: NCH₃ 4); 3.97 (s, 3H: NCH₃); from 4.15 to 4.40 (m, 4H: COOCH₂ ethyl); 4.62 (dd, $J=9$ and 6 Hz, 1H: 3 α); 4.67 (br dd, $J=13$ and 7.5 Hz, 1H: 5 ϵ); 4.79 (m, $J=9$ and 7.5 Hz, 1H: 2 α); 4.93 (dd, $J=10$ and 1.5 Hz, 1H: 1 α); 5.15 (br d, $J=6$ Hz, 1H: 5 α); 5.34 (dd, $J=12.5$ and 4.5 Hz, 1H: 4 α); 5.88 (m, $J=7$ and 2.5 Hz, 1H: 1 β); 5.95 (d, $J=10$ Hz, 1H: 6 α); 6.60 (d, $J=9$ Hz, 1H: NH 2); 6.71 (d, $J=8.5$ Hz, 2H: H Aromatics in 4 ϵ); 7.03 (d, $J=8.5$ Hz, 2H: H Aromatics in 4 δ); from 7.10 to 7.30 (m, 5H: H Aromatics in 6); 7.37 (s, 1H: H5 of pyrrolyl); 8.03 (d, $J=10$ Hz, 1H: NH 1); 8.84 (d, $J=10$ Hz, 1H: NH 6).

Anal Calcd for C₅₁H₆₄N₈O₁₃:

C 61.43, H 6.47, N 11.24, O 20.86

Found: (toluene, 1.5%, water 2.1%)

C 61.88, H 6.50, N 11.06, O 20.20

N-Ethyl Pyrrole 10b

To a solution of *N*-ethyl 3-pyridinium pristinamycin I_A betaine **5b** (5.5 g, 6.14 mmol) in dichloroethane (40 ml), diethyl acetylenedicarboxylate (10.5 g, 61.5 mmol) was added. The mixture was refluxed for 21 hours, evaporated to dryness then purified by flash-chromatography by using toluene-ethanol (90:10) as eluant to yield 4.3 g (69% yield) of **10b** as beige solid (mp 162°C).

¹H NMR (400 MHz, CDCl₃) δ : 0.23 (dd, $J=16$ and 6 Hz, 1H: 5 β); 0.90 (t, $J=7.5$ Hz, 3H: CH₃ 2 γ); from 1.15 to 1.40 (m, 2H: 3 β and 3 γ); 1.25 (d, $J=6.5$ Hz, 3H: CH₃ 1 γ); 1.33 and 1.37 (2t, $J=7$ Hz, 3H each: CH₃ diethoxy); 1.53 (m, 1H: 3 γ); 1.53 (t, $J=7$ Hz, 3H: CH₃ ethyl); 1.65 and 1.75 (2 m, 1H each: CH₂ 2 β); 2.02 (m, 1H: 3 β); 2.09 (m, 1H: 5 δ); 2.20 (d, $J=16$ Hz, 1H: 5 β); 2.22 (m,

$J=16$ Hz, 1H: 5 δ); 2.73 (m, $J=13$ and 4 Hz, 1H: 5 ϵ); 2.87 (s, 6H: N(CH₃)₂); 2.94 (dd, $J=12$ and 4 Hz, 1H: 4 β); 3.18 and 3.45 (2m, 1H each: CH₂ 3 δ); 3.20 (t, $J=12$ Hz, 1H: 4 β); 3.25 (s, 3H: NCH₃ 4); from 4.15 to 4.35 (m, 4H: COOCH₂ of diethoxy); 4.35 (q, $J=7$ Hz, 2H: NCH₂ ethyl); 4.60 (dd, $J=8$ and 5 Hz, 1H: 3 α); 4.65 (bdd, $J=13$ and 7.5 Hz, 1H: 5 ϵ); 4.78 (m, $J=9$ and 7.5 Hz, 1H: 2 α); 4.95 (dd, $J=9.5$ and 1.5 Hz, 1H: 1 α); 5.15 (brd, $J=6$ Hz, 1H: 5 α); 5.33 (dd, $J=12$ and 4 Hz, 1H: 4 α); 5.88 (m, $J=6.5$ and 1.5 Hz, 1H: 1 β); 6.02 (d, $J=10$ Hz, 1H: 6 α); 6.67 (d, $J=9$ Hz, 1H: NH 2); 6.70 (d, $J=8.5$ Hz, 2H: H Aromatics in 4 ϵ); 7.04 (d, $J=8.5$ Hz, 2H: H Aromatics in 4 δ); from 7.10 to 7.30 (m, 5H: H Aromatics in 6); 7.42 (s, 1H: H 5 of pyrrolyl); 8.07 (d, $J=9.5$ Hz, 1H: NH 1); 8.84 (d, $J=10$ Hz, 1H: NH 6).

Anal. Calcd for C₅₂H₆₆N₈O₁₃:

C 61.77, H 6.58, N 11.08, O 20.57

Found: (H₂O 1.5%)

C 61.75, H 6.80, N 10.45, O 20.30

Antibacterial Activity

The *in vitro* activities were determined as described by ERICSSON and SHERRIS¹⁹. Strains tested were IP 8302: *Staphylococcus aureus* sensitive, *S. aureus* Faur.: MLS_B inducibly resistant (erythromycin resistant: Ery^r), *S. aureus* Duc.: MLS_B constitutively resistant (Ery^r).

Acknowledgments

We express our appreciation to the Analytical Department for elemental analysis, NMR, IR and mass spectral analyses and to N. BERTHAUD and O. ROLIN for antibacterial testing.

References

- 1) VAZQUEZ, D.: The streptogramin family of antibiotics. *In* Antibiotics. Eds. J. N. CORCORAN and F. E. HAHN, Springer, Berlin, Heidelberg, New-York, Vol. III: 521~534, 1975
- 2) COCITO, C.: Antibiotics of the virginiamycin family, inhibitors which contain synergistic components. *Microbiological Reviews* 43(2): 145~198, 1979
- 3) PARIS, J.-M.; J.-C. BARRIÈRE, C. SMITH & P. E. BOST: The chemistry of pristinamycins. *In* Recent Progress in The Chemical Synthesis of Antibiotics. Eds. G. LUKACS and M. OHNO, Springer, Verlag: Berlin, Heidelberg, New York, pp.183~248, 1991
- 4) BARRIÈRE, J.-C.; D. BOUANCHAUD, J.-F. DESNOTTES & J.-M. PARIS: Streptogramin analogues. *Expert Opin. Invest. Drugs* 3(2): 115~121, 1994
- 5) DI GIAMBATTISTA, M.; E. NYSSSEN, A. PECHER & C. COCITO: Affinity labelling of the virginiamycin S binding site on bacterial ribosome. *Biochemistry* 29: 9203~9211, 1990
- 6) DI GIAMBATTISTA, M.; Y. ENGELBORGHES, E. NYSSSEN, K. CLAYS & C. COCITO: Interaction between virginiamycin S and ribosomes is partly provided by a salt bridge with a Mg²⁺ Ion. *Biochemistry* 30: 7277~7282, 1991
- 7) VANNUFFEL, P.; M. DI GIAMBATTISTA & C. COCITO: The role of RNA bases in the interaction of peptidyltransferase inhibitors with bacterial ribosome. *J. Biol. Chem.* 267: 16114~16120, 1992
- 8) BARRIÈRE, J.-C. & J. M. PARIS: RP 59500 and related semisynthetic streptogramins. *Drugs of the Future* 18(9): 883~885, 1993
- 9) BARRIÈRE, J.-C.; E. BACQUÉ, J. M. PARIS, F. ALBANO, J. FRANÇOIS, C. MOLHERAT & M. VUILHORGNE: Preparation of des-3-hydroxy-picolinoyl pristinamycins I. *Tetrahedron Lett.* 35: 9565~9568, 1994
- 10) BODANSZKY, M. (Squibb E. R. and Sons, Inc.); Brit. patent 1,157,912 (Cl. C07d), Jul. 09, 1969, Appl. 14 Sept. 1966
- 11) BODANSZKY, M. (Squibb, E. R. and Sons, Inc.); U.S. patent 3,420,816 (Cl. 260~239~3), 7 Jan. 1969, Appl. 15 Mars 1965
- 12) Squibb, E. R. & Sons, Inc.: French patent, 1,505,434 (Cl. C07d, A61k), 15 Dec. 1967, Appl. 15 Sept. 1966
- 13) ANTEUNIS, M. J. O. & N. K. SHARMA: Benzoylation of virginiamycin S1. *Bull. Soc. Chim. Belg.* 97: 365~369, 1988
- 14) SHARMA, N. K. & M. J. O. ANTEUNIS: A search for phenolic protection in virginiamycin S. *Bull. Soc. Chim. Belg.* 98: 463~479, 1989
- 15) DENNIS, N.; A. R. KATRITZKY & Y. TAKEUCI: Synthetic applications of heteroaromatic betaines with six-membered rings. *Ang. Chem. Int. Ed. Engl.* 15 (1): 1~9, 1976
- 16) KATRITZKY, A. R. & N. DENNIS: Cycloaddition reactions of heteroaromatic six-membered rings. *Chem. Rev.* 89: 827~821, 1989
- 17) RAMSDEN, C. A.: Heterocyclic betaine derivatives of alternant hydrocarbons. *In* Advances in Heterocyclic Chemistry, Vol. 26, pp. 1~113, 1980
- 18) ANTEUNIS, M. J. O.; R. E. A. CALLENS & D. K. TAVERNIER: Solution conformation of virginiamycins (staphylomycins). *Eur. J. Biochem.* 58: 259~268, 1975
- 19) ERICSSON, H. M. & J. C. SHERRIS: International collaborative study on antibiotic sensitivity testing, *acta path. Microbiologica. Scandinavica, Sect. B, Suppl.* 217: 11~90, 1971